A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

NCT ID: NCT07218380

Last Updated: 2025-11-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE3

Total Enrollment

450 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-11-30

Study Completion Date

2033-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread.

Vepugratinib or placebo will be administered in combination with enfortumab vedotin and pembrolizumab.

Study participation could last up to approximately 6 years.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carcinoma, Transitional Cell Urinary Bladder Neoplasms Neoplasm Metastasis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

FGFR3 Advanced Urothelial Carcinoma Metastatic Urothelial Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators
There will be an open-label safety lead in.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vepugratinib + Enfortumab Vedotin (EV) + Pembrolizumab

Vepugratinib administered orally, and EV + pembrolizumab administered by intravenous (IV) infusion.

Group Type EXPERIMENTAL

Vepugratinib

Intervention Type DRUG

Administered orally

EV

Intervention Type DRUG

Administered by IV infusion

Pembrolizumab

Intervention Type DRUG

Administered by IV infusion

Placebo + EV + Pembrolizumab

Placebo administered orally, and EV + pembrolizumab administered by IV infusion.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

Administered orally

EV

Intervention Type DRUG

Administered by IV infusion

Pembrolizumab

Intervention Type DRUG

Administered by IV infusion

Vepugratinib + EV + Pembrolizumab (Safety Lead In)

Vepugratinib administered orally with EV + pembrolizumab administered IV

Group Type EXPERIMENTAL

Vepugratinib

Intervention Type DRUG

Administered orally

EV

Intervention Type DRUG

Administered by IV infusion

Pembrolizumab

Intervention Type DRUG

Administered by IV infusion

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vepugratinib

Administered orally

Intervention Type DRUG

Placebo

Administered orally

Intervention Type OTHER

EV

Administered by IV infusion

Intervention Type DRUG

Pembrolizumab

Administered by IV infusion

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Have histologically confirmed, unresectable locally advanced or metastatic urothelial cancer (mUC). Individuals with mixed histology other than small cell or neuroendocrine carcinoma are eligible if a urothelial component is present.
* Have a qualifying fibroblast growth factor receptor 3 (FGFR3) genetic alteration determined via molecular testing from a tumor or blood sample obtained at or any time after diagnosis of advanced or metastatic urothelial cancer.
* Have measurable disease by investigator assessment defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
* Have adequate laboratory parameters

Exclusion Criteria

* Have received prior systemic therapy for locally advanced or metastatic urothelial cancer (mUC).
* Have any unresolved toxicities greater than Grade 1 Common Terminology Criteria for Adverse Events (\[CTCAE\] version 5.0) from prior neoadjuvant or adjuvant systemic therapy.
* Have ongoing sensory or motor neuropathy of Grade 2 or higher
* Have untreated or uncontrolled central nervous system (CNS) involvement or any history of leptomeningeal disease.
* Current evidence corneal keratopathy or retinal disorder confirmed by ocular examination at screening.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Eli Lilly and Company

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)

Role: STUDY_DIRECTOR

Eli Lilly and Company

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clearview Cancer Institute

Huntsville, Alabama, United States

Site Status

The University of Arizona Cancer Center - North Campus

Tucson, Arizona, United States

Site Status

TRIO-US (Translational Research in Oncology-US)

Los Angeles, California, United States

Site Status

UCLA Hematology/Oncology - Santa Monica

Los Angeles, California, United States

Site Status

UCSF Medical Center at Mission Bay

San Francisco, California, United States

Site Status

Hunt Cancer Institute, an Affiliate of Cedars-Sinai Cancer (TMPN)

Torrance, California, United States

Site Status

AdventHealth Medical Group - Porter

Denver, Colorado, United States

Site Status

Colorado West Healthcare System - Grand Valley Oncology

Grand Junction, Colorado, United States

Site Status

AdventHealth Celebration

Celebration, Florida, United States

Site Status

St. Luke's Cancer Institute: Boise

Boise, Idaho, United States

Site Status

University of Illinois at Chicago

Chicago, Illinois, United States

Site Status

Parkview Research Center at Parkview Regional Medical Center

Fort Wayne, Indiana, United States

Site Status

Indiana University Melvin and Bren Simon Cancer Center

Indianapolis, Indiana, United States

Site Status

Franciscan Health

Indianapolis, Indiana, United States

Site Status

Mary Bird Perkins Cancer Center

Baton Rouge, Louisiana, United States

Site Status

Johns Hopkins Hospital

Baltimore, Maryland, United States

Site Status

Massachusetts General Hospital

Boston, Massachusetts, United States

Site Status

Karmanos Cancer Institute

Detroit, Michigan, United States

Site Status

Washington University

St Louis, Missouri, United States

Site Status

Comprehensive Cancer Centers of Nevada

Las Vegas, Nevada, United States

Site Status

Icahn School of Medicine at Mount Sinai

New York, New York, United States

Site Status

Columbia University Irving Medical Center

New York, New York, United States

Site Status

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Site Status

Weill Cornell Medical College

New York, New York, United States

Site Status

The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer -T

Columbus, Ohio, United States

Site Status

Providence Portland Medical Center

Portland, Oregon, United States

Site Status

Providence St. Vincent Medical Center

Portland, Oregon, United States

Site Status

Kaiser Permanente Interstate Medical Office Central

Portland, Oregon, United States

Site Status

Oregon Health and Science University

Portland, Oregon, United States

Site Status

Lancaster General Hospital - Ann B Barshinger Cancer Institute

Lancaster, Pennsylvania, United States

Site Status

AHN Allegheny General Hospital

Pittsburgh, Pennsylvania, United States

Site Status

Avera Cancer Institute- Research

Sioux Falls, South Dakota, United States

Site Status

Tennessee Oncology Chattanooga

Chattanooga, Tennessee, United States

Site Status

Sarah Cannon Research Institute

Nashville, Tennessee, United States

Site Status

SCRI Oncology Partners

Nashville, Tennessee, United States

Site Status

Tennessee Oncology

Nashville, Tennessee, United States

Site Status

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Site Status

USO-Texas Oncology-Central/South Texas

Austin, Texas, United States

Site Status

World Research Link

Baytown, Texas, United States

Site Status

Parkland Health and Hospital System

Dallas, Texas, United States

Site Status

UT Southwestern Medical Center

Dallas, Texas, United States

Site Status

US Oncology Research Network

The Woodlands, Texas, United States

Site Status

USO - Texas Oncology - Northeast Texas

Tyler, Texas, United States

Site Status

USO - Virginia Oncology Associates

Norfolk, Virginia, United States

Site Status

Box Hill Hospital

Box Hill, , Australia

Site Status

Mater Misericordiae Limited

Brisbane, , Australia

Site Status

Austin Health

Heidelberg, , Australia

Site Status

Macquarie University

Macquarie, , Australia

Site Status

Sir Charles Gairdner Hospital

Perth, , Australia

Site Status

Prince of Wales Hospital

Randwick, , Australia

Site Status

Fundação Pio XII - Hospital de Câncer de Barretos

Barretos, , Brazil

Site Status

CPAM - Centro de Pesquisas da Amazônia

Belém, , Brazil

Site Status

Oncocentro de Minas Gerais

Belo Horizonte, , Brazil

Site Status

Hospital Mario Penna

Belo Horizonte, , Brazil

Site Status

Hospital Tacchini

Bento Gonçalves, , Brazil

Site Status

Centro Integrado de Oncologia de Curitiba

Curitiba, , Brazil

Site Status

IOP Pesquisa

Curitiba, , Brazil

Site Status

Centro Paraibano De Oncologia - Oncoclínicas

João Pessoa, , Brazil

Site Status

Hospital de Cancer de Londrina

Londrina, , Brazil

Site Status

Liga Norte Riograndense Contra o Câncer

Natal, , Brazil

Site Status

Centro Gaucho Integrado De Oncologia, Hematologia, Ensino E Pesquisa

Porto Alegre, , Brazil

Site Status

Hospital São Lucas da PUCRS

Porto Alegre, , Brazil

Site Status

Hospital Nossa Senhora da Conceição

Porto Alegre, , Brazil

Site Status

Instituto Nacional de Câncer José Alencar Gomes da Silva - INCA

Rio de Janeiro, , Brazil

Site Status

Instituto D'Or Pesquisa e Ensino

Rio de Janeiro, , Brazil

Site Status

Nucleo de Oncologia da Bahia

Salvador, , Brazil

Site Status

Clinica Amo - Rio Vermelho

Salvador, , Brazil

Site Status

Instituto de Oncologia Saint Gallen

Santa Cruz do Sul, , Brazil

Site Status

Centro de Oncologia - CEON+ - Unidade São Caetano do Sul

São Caetano do Sul, , Brazil

Site Status

Instituto do Cancer Arnaldo Vieira de Carvalho

São Paulo, , Brazil

Site Status

Icesp - Instituto Do Câncer Do Estado de São Paulo

São Paulo, , Brazil

Site Status

Hospital BP

São Paulo, , Brazil

Site Status

Hospital Alemao Oswaldo Cruz

São Paulo, , Brazil

Site Status

Centro Paulista de Oncologia Clínica

São Paulo, , Brazil

Site Status

IBCC - Núcleo de Pesquisa e Ensino

São Paulo, , Brazil

Site Status

Hamilton Health Sciences-Juravinski Cancer Centre

Hamilton, , Canada

Site Status

Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus

Québec, , Canada

Site Status

BC Cancer Vancouver

Vancouver, , Canada

Site Status

Peking University First Hospital

Beijing, , China

Site Status

Peking University Third Hospital

Beijing, , China

Site Status

Beijing Cancer hospital

Beijing, , China

Site Status

Beijing GoBroad Hospital

Beijing, , China

Site Status

The First Hospital of Jilin University

Changchun, , China

Site Status

Xiangya Hospital Central South University

Changsha, , China

Site Status

Hunan Cancer Hospital

Changsha, , China

Site Status

West China Hospital, Sichuan University

Chengdu, , China

Site Status

The First Affiliated Hospital of Chongqing Medical University

Chongqing, , China

Site Status

Chongqing University Cancer Hospital

Chongqing, , China

Site Status

The First Affiliated Hospital of Guangzhou Medical University

Guangzhou, , China

Site Status

Zhujiang Hospital

Guangzhou, , China

Site Status

Sun Yat-Sen University Cancer Centre

Guangzhou, , China

Site Status

Zhejiang Provincial People's Hospital

Hangzhou, , China

Site Status

Sir Run Run Shaw Hospital

Hangzhou, , China

Site Status

Zhejiang Cancer Hospital

Hangzhou, , China

Site Status

Harbin Medical University Cancer Hospital

Harbin, , China

Site Status

Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School

Nanjing, , China

Site Status

Guangxi Medical University Affiliated Tumor Hospital

Nanning, , China

Site Status

Ningbo First Hospital

Ningbo, , China

Site Status

Huashan Hospital, Fudan University

Shanghai, , China

Site Status

Shanghai Tenth People's Hospital

Shanghai, , China

Site Status

Renji Hospital Shanghai Jiao Tong University School of Medicine

Shanghai, , China

Site Status

The Second Hospital of Tianjin Medical University

Tianjin, , China

Site Status

Tongji Hospital Tongji Medical,Science & Technology

Wuhan, , China

Site Status

Masarykuv onkologicky ustav

Brno, , Czechia

Site Status

Fakultni nemocnice Hradec Kralove

Hradec Králové, , Czechia

Site Status

Fakultni nemocnice Olomouc

Olomouc, , Czechia

Site Status

Fakultni nemocnice Kralovske Vinohrady

Prague, , Czechia

Site Status

Fakultni Thomayerova nemocnice

Prague, , Czechia

Site Status

Fakultni nemocnice Motol

Prague, , Czechia

Site Status

Aalborg Universitetshospital, Syd

Aalborg, , Denmark

Site Status

Aarhus Universitetshospital, Skejby

Aarhus, , Denmark

Site Status

Rigshospitalet

Copenhagen, , Denmark

Site Status

Herlev and Gentofte Hospital

Copenhagen, , Denmark

Site Status

Næstved Sygehus

Næstved, , Denmark

Site Status

Institut de Cancérologie de l'Ouest

Angers, , France

Site Status

CHU de Bordeaux Hop St ANDRE

Bordeaux, , France

Site Status

Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest

Bordeaux, , France

Site Status

CHRU de Brest

Brest, , France

Site Status

Centre François Baclesse

Caen, , France

Site Status

Centre Oscar Lambret

Lille, , France

Site Status

Centre Leon Berard

Lyon Cedex08, , France

Site Status

Institut Paoli-Calmettes

Marseille, , France

Site Status

Centre Hospitalier Universitaire de Nîmes - Institut de Cancérologie du Gard - Hôpital Universitaire Carém -T

Nîmes, , France

Site Status

Centre Hospitalier Lyon Sud

Pierre-Bénite, , France

Site Status

Oncopole Claudius Regaud

Toulouse, , France

Site Status

Gustave Roussy

Villejuif, , France

Site Status

Helios Klinikum Bad Saarow

Bad Saarow, , Germany

Site Status

Charité Universitaetsmedizin Berlin - Campus Mitte

Berlin, , Germany

Site Status

Evangelisches Krankenhaus Bielefeld - Johannesstift

Bielefeld, , Germany

Site Status

Johanniter-Krankenhaus

Bonn, , Germany

Site Status

Studienzentrum Bayenthal Urologische Partnerschaft Köln

Cologne, , Germany

Site Status

Universitaetsklinikum Carl Gustav Carus, Technischen Universitaet Dresden

Dresden, , Germany

Site Status

Urologicum Duisburg Fachärztesozietät - Walsum

Duisburg, , Germany

Site Status

Universitaetsklinikum Duesseldorf

Düsseldorf, , Germany

Site Status

Universitaetsklinikum Erlangen

Erlangen, , Germany

Site Status

Universitaetsklinikum Essen

Essen, , Germany

Site Status

Krankenhaus Nordwest GmbH

Frankfurt, , Germany

Site Status

Universitaetsklinikum Freiburg

Freiburg im Breisgau, , Germany

Site Status

Universitätsmedizin Greifswald

Greifswald, , Germany

Site Status

Universitaetsklinikum Hamburg-Eppendorf

Hamburg, , Germany

Site Status

NCT

Heidelberg, , Germany

Site Status

InVO Institut für Versorgungsforschung in der Onkologie

Koblenz, , Germany

Site Status

Universitätsklinikum Schleswig-Holstein

Lübeck, , Germany

Site Status

Klinikum Rechts Der Isar Der Technischen Universität München

Munich, , Germany

Site Status

Universitätsklinikum Münster - Albert Schweitzer Campus

Münster, , Germany

Site Status

Klinikum Nürnberg Nord

Nuremberg, , Germany

Site Status

Studienpraxis Urologie

Nürtingen, , Germany

Site Status

Universitätsmedizin Rostock

Rostock, , Germany

Site Status

Universitaetsklinikum Tuebingen

Tübingen, , Germany

Site Status

Universitaetsklinikum Ulm

Ulm, , Germany

Site Status

Universitaetsklinikum Wuerzburg

Würzburg, , Germany

Site Status

Semmelweis Egyetem

Budapest, , Hungary

Site Status

Országos Onkológiai Intézet

Budapest, , Hungary

Site Status

Debreceni Egyetem Klinikai Kozpont

Debrecen, , Hungary

Site Status

Szabolcs Szatmár Bereg Vármegyei Oktatókórház

Nyíregyháza, , Hungary

Site Status

Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ

Szeged, , Hungary

Site Status

Instituto Tumori Giovanni Paolo II

Bari, , Italy

Site Status

Fondazione IRCCS Istituto Nazionale dei Tumori

Milan, , Italy

Site Status

Ospedale San Raffaele

Milan, , Italy

Site Status

Azienda Ospedaliera Universitaria Federico II

Napoli, , Italy

Site Status

Istituto Oncologico Veneto IRCCS

Padua, , Italy

Site Status

Azienda Ospedaliera Universitaria Pisana

Pisa, , Italy

Site Status

Fondazione Policlinico Universitario Agostino Gemelli

Roma, , Italy

Site Status

Istituto Nazionale Tumori Regina Elena

Rome, , Italy

Site Status

National Cancer Center Hospital

Chūōku, , Japan

Site Status

Kyushu University Hospital

Fukuoka, , Japan

Site Status

Hirosaki University Hospital

Hirosaki, , Japan

Site Status

Kanazawa University Hospital

Kanazawa, , Japan

Site Status

National Cancer Center Hospital East

Kashiwa, , Japan

Site Status

St. Marianna University Hospital

Kawasaki, , Japan

Site Status

Kagawa University Hospital

Kita-ku, , Japan

Site Status

Kobe City Medical Center General Hospital

Kobe, , Japan

Site Status

The Cancer Institute Hospital of JFCR

Kōtoku, , Japan

Site Status

Kyoto University Hospital

Kyoto, , Japan

Site Status

National Hospital Organization Shikoku Cancer Center

Matsuyama, , Japan

Site Status

Aichi Cancer Center Hospital

Nagoya, , Japan

Site Status

Niigata University Medical & Dental Hospital

Niigata, , Japan

Site Status

Osaka International Cancer Institute

Osaka, , Japan

Site Status

Gunma Prefectural Cancer Center

Otashi, , Japan

Site Status

Hokkaido University Hospital

Sapporo, , Japan

Site Status

Tohoku University Hospital

Sendai, , Japan

Site Status

Iwate Medical University Hospital

Shiwa-gun Yahaba-cho, , Japan

Site Status

Tokushima University Hospital

Tokushima, , Japan

Site Status

Tsukuba University Hospital

Tsukuba, , Japan

Site Status

Amsterdam UMC, locatie VUmc

Amsterdam, , Netherlands

Site Status

Amphia Ziekenhuis, locatie Breda Molengracht

Breda, , Netherlands

Site Status

Radboudumc

Nijmegen, , Netherlands

Site Status

Erasmus Medisch Centrum

Rotterdam, , Netherlands

Site Status

IN VIVO

Bydgoszcz, , Poland

Site Status

Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie

Koszalin, , Poland

Site Status

Pratia MCM Krakow

Krakow, , Poland

Site Status

AIDPORT Sp. z o.o.

Skórzewo, , Poland

Site Status

GYNCENTRUM Szpital

Sosnowiec, , Poland

Site Status

Luxmed Onkologia sp. z o. o.

Warsaw, , Poland

Site Status

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie

Warsaw, , Poland

Site Status

WSD MEDI

Warsaw, , Poland

Site Status

Medical Concierge Centrum Medyczne

Warsaw, , Poland

Site Status

Szpital Grochowski im. dr med. Rafała Masztaka SPZOZ

Warsaw, , Poland

Site Status

Wojskowy Instytut Medyczny Państwowy Instytut Badawczy

Warsaw, , Poland

Site Status

Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu

Wrocaw, , Poland

Site Status

National Cancer Center

Goyang-si, , South Korea

Site Status

Chungnam national university hospital

Junggu, , South Korea

Site Status

Gachon University Gil Medical Center

Namdong-gu, , South Korea

Site Status

Seoul National University Bundang Hospital

Seongnam, , South Korea

Site Status

Seoul National University Hospital

Seoul, , South Korea

Site Status

Severance Hospital, Yonsei University Health System

Seoul, , South Korea

Site Status

Asan Medical Center

Seoul, , South Korea

Site Status

Samsung Medical Center

Seoul, , South Korea

Site Status

The Catholic Univ. of Korea Seoul St. Mary's Hospital

Seoul, , South Korea

Site Status

Ewha Womans University Mokdong Hospital

Seoul, , South Korea

Site Status

Hospital Infanta Cristina

Badajoz, , Spain

Site Status

Institut Català d'Oncologia (ICO) - Badalona

Badalona, , Spain

Site Status

OSI Ezkerraldea-Enkarterri-Cruces - Hospital Universitario Cruces

Barakaldo, , Spain

Site Status

Hospital Universitari Vall d'Hebron

Barcelona, , Spain

Site Status

Hospital Clínic de Barcelona

Barcelona, , Spain

Site Status

Hospital de la Santa Creu i Sant Pau

Barcelona, , Spain

Site Status

Hospital Universitario Reina Sofia

Córdoba, , Spain

Site Status

Hospital General Universitario de Elche

Elche, , Spain

Site Status

Institut Català d'Oncologia (ICO) - Girona

Girona, , Spain

Site Status

Instituto Catalan de Oncologia - Hospital Duran i Reynals

Hospitalet, , Spain

Site Status

Hospital Insular de Gran Canaria

Las Palmas de Gran Canaria, , Spain

Site Status

Hospital La Princesa

Madrid, , Spain

Site Status

Hospital General Universitario Gregorio Marañon

Madrid, , Spain

Site Status

MD Anderson Cancer Center

Madrid, , Spain

Site Status

Hospital Universitario Ramón y Cajal

Madrid, , Spain

Site Status

Hospital Clinico San Carlos

Madrid, , Spain

Site Status

Hospital Universitario 12 de Octubre

Madrid, , Spain

Site Status

Hospital Universitario La Paz

Madrid, , Spain

Site Status

H.R.U Málaga - Hospital General

Málaga, , Spain

Site Status

Complejo Hospitalario de Navarra

Pamplona, , Spain

Site Status

Hospital Universitario Quironsalud Madrid

Pozuelo de Alarcón, , Spain

Site Status

Hospital Universitari Sant Joan de Reus

Reus, , Spain

Site Status

Hospital Universitario Marqués de Valdecilla

Santander, , Spain

Site Status

CHUS - Hospital Clinico Universitario

Santiago de Compostela, , Spain

Site Status

Hospital Universitario Virgen Del Rocio

Seville, , Spain

Site Status

Hospital Arnau de Vilanova

Valencia, , Spain

Site Status

Kaohsiung Medical University Chung-Ho Memorial Hospital

Kaohsiung City, , Taiwan

Site Status

Chang Gung Memorial Hospital at Kaohsiung

Kaohsiung Niao Sung Dist, , Taiwan

Site Status

China Medical University Hospital

Taichung, , Taiwan

Site Status

Taichung Veterans General Hospital

Taichung, , Taiwan

Site Status

National Cheng Kung University Hospital

Tainan, , Taiwan

Site Status

Chi Mei Medical Center

Tainan, , Taiwan

Site Status

Chi Mei Hospital - Liouying Branch

Tainan, , Taiwan

Site Status

National Taiwan University Hospital

Taipei, , Taiwan

Site Status

National Taiwan University Cancer Center (NTUCC)

Taipei, , Taiwan

Site Status

Taipei Veterans General Hospital

Taipei, , Taiwan

Site Status

Chang Gung Medical Foundation-Linkou Branch

Taoyuan District, , Taiwan

Site Status

Adana Medical Park Seyhan Hastanesi

Adana, , Turkey (Türkiye)

Site Status

Sakarya University School of Medicine

Adapazarı, , Turkey (Türkiye)

Site Status

Ankara University Health Practice and Research Hospitals

Ankara, , Turkey (Türkiye)

Site Status

Ankara Bilkent Şehir Hastanesi

Ankara, , Turkey (Türkiye)

Site Status

Antalya Egitim ve Arastırma Hastanesi

Antalya, , Turkey (Türkiye)

Site Status

Memorial Diyarbakır Hastanesi

Diyarbakır, , Turkey (Türkiye)

Site Status

Trakya University

Edirne, , Turkey (Türkiye)

Site Status

Gaziantep Universitesi Sahinbey Arastirma ve Uygulama Hastanesi

Gaziantep, , Turkey (Türkiye)

Site Status

Dr. Lutfi Kirdar Kartal Training and Research Hospital

Istanbul, , Turkey (Türkiye)

Site Status

Marmara Universitesi Pendik Egitim Arastirma Hastanesi

Istanbul, , Turkey (Türkiye)

Site Status

zmir Katip Çelebi Üniversitesi Atatürk Eitim Ve Aratrma Hastanesi

Izmir, , Turkey (Türkiye)

Site Status

Huddersfield Royal Infirmary

Huddersfield, , United Kingdom

Site Status

St Bartholomew's Hospital

London, , United Kingdom

Site Status

University College London Hospital

London, , United Kingdom

Site Status

Royal Marsden Hospital (Sutton)

London, , United Kingdom

Site Status

Royal Marsden Hospital (Chelsea)

London, , United Kingdom

Site Status

The Christie NHS Foundation Trust

Manchester, , United Kingdom

Site Status

Weston Park Hospital

Sheffield, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Brazil Canada China Czechia Denmark France Germany Hungary Italy Japan Netherlands Poland South Korea Spain Taiwan Turkey (Türkiye) United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

Role: CONTACT

Phone: 1-317-615-4559

Email: [email protected]

Physicians interested in becoming principal investigators please contact

Role: CONTACT

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Role: primary

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

J4G-MC-JZVD

Identifier Type: OTHER

Identifier Source: secondary_id

2025-522855-25-00

Identifier Type: CTIS

Identifier Source: secondary_id

27333

Identifier Type: -

Identifier Source: org_study_id